Search results
Showing 31 to 42 of 42 results for bortezomib multiple myeloma
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
Discontinued Reference number: GID-TA10171
Discontinued Reference number: GID-TA10502
Past technology appraisal appeals and decisions
transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma...
In development Reference number: GID-TA10568 Expected publication date: TBC
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.
This guidance has been updated and replaced by NICE technology appraisal guidance 427.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.